A controversy surrounds Exparel, a long-acting local anesthetic, primarily concerning its marketing practices and allegations of off-label promotion [1]. Specifically, the U.S. Department of Justice has been involved in investigating claims that Pacira BioSciences, the manufacturer of Exparel, improperly promoted the drug for unapproved uses [2].
What are the allegations against Exparel's manufacturer?
The core of the controversy involves allegations that Pacira BioSciences engaged in aggressive marketing tactics to promote Exparel for indications not approved by the U.S. Food and Drug Administration (FDA) [1][2]. These accusations suggest that the company may have encouraged healthcare providers to use Exparel in ways not supported by clinical trials or FDA approval, potentially leading to increased costs and unproven benefits for certain procedures [2].
What is Exparel used for, and what were the alleged off-label uses?
Exparel is approved for specific uses, including providing post-surgical analgesia following certain orthopedic surgical procedures and oral surgical procedures [1]. The controversy centers on claims that Pacira BioSciences promoted Exparel for a wider range of surgical procedures, including those where its efficacy and safety were not definitively established by the FDA [2].
How did the government get involved in the Exparel controversy?
The U.S. Department of Justice, through the U.S. Attorney's Office for the District of Massachusetts, investigated these marketing practices [2]. Such investigations are typically initiated based on whistleblower complaints or other intelligence suggesting violations of federal healthcare laws, including the False Claims Act [2].
What were the potential consequences of the off-label promotion?
Off-label promotion can have several consequences. For patients, it could mean exposure to treatments with unknown risks or limited proven benefits [2]. For healthcare providers and institutions, it can lead to improper billing of federal healthcare programs, potentially violating the False Claims Act [2]. For the manufacturer, it can result in significant fines, penalties, and mandated changes to marketing and compliance practices [2].
Has there been a resolution to the Exparel controversy?
In December 2021, Pacira BioSciences announced it had reached a settlement with the U.S. Department of Justice to resolve the investigation into its marketing of Exparel [1]. The company agreed to pay $2.9 million as part of the settlement, which also included entering into a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services [1]. This agreement requires Pacira to implement a comprehensive compliance program for several years.
What is the significance of the corporate integrity agreement?
The corporate integrity agreement (CIA) is a crucial component of the resolution. It imposes strict oversight and reporting requirements on Pacira BioSciences for a specified period [1]. This typically involves appointing an independent compliance consultant, conducting regular audits of its marketing and promotional activities, and reporting findings to the government. The CIA aims to ensure that the company adheres to all applicable laws and regulations moving forward and to prevent future violations [1].
What does this settlement mean for Exparel's availability?
The settlement resolves the government's investigation and does not restrict the approved uses of Exparel [1]. Patients and healthcare providers can continue to use Exparel for its FDA-approved indications. The controversy primarily focused on the marketing and promotional practices surrounding the drug, not its underlying efficacy or safety for approved uses.
What are Exparel's approved uses and its mechanism of action?
Exparel (bupivacaine liposome injectable suspension) is a non-opioid local anesthetic indicated for single-dose administration into the surgical site for post-operative pain management [1]. It is approved for use in adults following orthopedic surgical procedures and oral and maxillofacial surgery [1]. Exparel works by releasing bupivacaine slowly over an extended period, providing pain relief for up to 72 hours after administration, unlike standard bupivacaine which has a much shorter duration of action [1].
Sources:
1. DrugPatentWatch.com
2. United States Department of Justice